Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP

Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 First Quarter Financial Results

Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial

Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, 2/9/2022

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints

Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71

Anavex Life Sciences Promotes Dr. Kaufmann to CSO and Appoints Dr. Hammond as CMO

Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference

Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference